Literature DB >> 22683148

Hype or hope? Ethical and practical considerations with clinical research in women with diminished ovarian reserve.

Norbert Gleicher, David H Barad.   

Abstract

This communication suggests that investigations of treatments for women with diminished functional ovarian reserve (DOR) call for specific practical and ethical considerations, as women with DOR, because of limited remaining reproductive life spans, appropriately feel under time constraints. Another medical journal recently published an opinion piece on the use of dehydroepiandrosterone in women with DOR, raising important questions about what approaches should be taken to develop best available evidence in such patients. Their manuscript offers an excellent opportunity to consider ethical and clinical aspects of study design in clinical circumstances where patients have little to lose but face the promise of considerable gains in clinical pregnancy chances if effective treatments can be developed. This commentary concludes that, in such circumstances, common sense as well as ethical considerations support the introduction of new treatments into the clinical mainstream even in absence of prospectively randomized studies if lower levels of evidence are supportive of positive treatment effects.
Copyright © 2012 Reproductive Healthcare Ltd. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22683148     DOI: 10.1016/j.rbmo.2012.04.003

Source DB:  PubMed          Journal:  Reprod Biomed Online        ISSN: 1472-6483            Impact factor:   3.828


  3 in total

1.  Fertility interventions 'add-ons' in clinical ART practice: Ethical, Moral and Commercial Considerations.

Authors:  Bindu N Chimote; Natchandra M Chimote
Journal:  J Assist Reprod Genet       Date:  2021-08-13       Impact factor: 3.357

2.  Evidence-based reproductive medicine: a critical appraisal.

Authors:  M Dhont
Journal:  Facts Views Vis Obgyn       Date:  2013

3.  The combination of dehydroepiandrosterone, transdermal testosterone, and growth hormone as an adjuvant therapy in assisted reproductive technology cycles in patients aged below 40 years with diminished ovarian reserve.

Authors:  Bülent Haydardedeoğlu; Ahmet Zeki Işık; Esra Bulgan Kılıçdağ
Journal:  Turk J Obstet Gynecol       Date:  2015-06-15
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.